382 related articles for article (PubMed ID: 23345050)
1. Prospective randomized comparison study of piperacillin/tazobactam and meropenem for healthcare-associated pneumonia in Japan.
Yamamoto Y; Izumikawa K; Morinaga Y; Nakamura S; Kurihara S; Imamura Y; Miyazaki T; Tsukamoto M; Kakeya H; Yanagihara K; Yasuoka A; Kohno S
J Infect Chemother; 2013 Apr; 19(2):291-8. PubMed ID: 23345050
[TBL] [Abstract][Full Text] [Related]
2. Meropenem versus piperacillin/tazobactam with or without immunoglobulin as second-line therapy for febrile neutropenia in pediatric patients.
Kobayashi R; Hori D; Sano H; Suzuki D; Kishimoto K; Kobayashi K
J Microbiol Immunol Infect; 2018 Aug; 51(4):473-477. PubMed ID: 28690028
[TBL] [Abstract][Full Text] [Related]
3. [A comparative study of tazobactam/piperacillin and piperacillin in bacterial pneumonia].
Oizumi K; Ohno T; Kawahara M; Kawaguchi S; Saisho M; Mitutake Y; Saito A; Tomizawa M; Koike T; Takebe K
Jpn J Antibiot; 1995 Apr; 48(4):449-81. PubMed ID: 7783313
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of piperacillin/tazobactam versus biapenem in late elderly patients with nursing- and healthcare-associated pneumonia.
Karino F; Miura K; Fuchita H; Koba N; Nishikawa E; Hotta T; Okimoto T; Iwamoto S; Tsubata Y; Tada M; Hamaguchi S; Honda T; Ohe M; Sutani A; Kuraki T; Takeyama H; Isobe T
J Infect Chemother; 2013 Oct; 19(5):909-15. PubMed ID: 23645226
[TBL] [Abstract][Full Text] [Related]
5. Nephrotoxicity induced by piperacillin–tazobactam in late elderly Japanese patients with nursing and healthcare associated pneumonia.
Karino F; Nishimura N; Ishihara N; Moriyama H; Miura K; Hamaguchi S; Sutani A; Kuraki T; Ikawa K; Morikawa N
Biol Pharm Bull; 2014; 37(12):1971-6. PubMed ID: 25590089
[TBL] [Abstract][Full Text] [Related]
6. A prospective randomized trial comparing piperacillin/tazobactam with meropenem as empirical antibiotic treatment of febrile neutropenic children and adolescents with hematologic and malignant disorders.
Sano H; Kobayashi R; Suzuki D; Hori D; Kishimoto K; Kobayashi K
Pediatr Blood Cancer; 2017 Jun; 64(6):. PubMed ID: 27873451
[TBL] [Abstract][Full Text] [Related]
7. [Bacteriological and clinical evaluation tazobactam/piperacillin in infectious diseases in surgical field].
Shinagawa N; Yura J; Mashita K; Matsuno S; Rikiyama T; Hirayama T; Tanaka T; Otsuka K; Iwai S; Nakagawa Y
Jpn J Antibiot; 1995 Mar; 48(3):346-67. PubMed ID: 7752449
[TBL] [Abstract][Full Text] [Related]
8. [Retrospective Analysis of Factors Decreasing the Efficacy of Tazobactam/Piperacillin for Pneumonia in Elderly Patients].
So M; Oda K; Ota K; Sakamoto N; Suzuki T
Yakugaku Zasshi; 2018; 138(4):581-588. PubMed ID: 29608008
[TBL] [Abstract][Full Text] [Related]
9. Tazobactam/piperacillin for moderate-to-severe pneumonia in patients with risk for aspiration: comparison with imipenem/cilastatin.
Ito I; Kadowaki S; Tanabe N; Haruna A; Kase M; Yasutomo Y; Tsukino M; Nakai A; Matsumoto H; Niimi A; Chin K; Ichiyama S; Mishima M
Pulm Pharmacol Ther; 2010 Oct; 23(5):403-10. PubMed ID: 20561917
[TBL] [Abstract][Full Text] [Related]
10. [Clinical effects of piperacillin and tazobactam/piperacillin on Haemophilus influenzae lower respiratory tract infection in pediatric patients].
Sudo F; Ishiwada N; Hoshino T; Fukasawa C; Inami Y; Hishiki H; Takeda N; Kurosaki T; Kohno Y
Kansenshogaku Zasshi; 2005 Sep; 79(9):637-43. PubMed ID: 16248372
[TBL] [Abstract][Full Text] [Related]
11. Retrospective investigation of the clinical effects of tazobactam/piperacillin and sulbactam/ampicillin on aspiration pneumonia caused by Klebsiella pneumoniae.
Tsukada H; Sakai K; Cho H; Kimura Y; Tetsuka T; Nakajima H; Ito K
J Infect Chemother; 2012 Oct; 18(5):715-21. PubMed ID: 22460828
[TBL] [Abstract][Full Text] [Related]
12. [A comparative study of tazobactam/piperacillin and piperacillin in chronic respiratory tract infections].
Oizumi K; Kawahara M; Kawaguchi S; Sigematsu H; Tanaka F; Sano N; Saito A; Hiraga Y; Ohmichi M; Inoue H
Jpn J Antibiot; 1995 Apr; 48(4):482-513. PubMed ID: 7783314
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial.
Alvarez-Lerma F; Insausti-Ordeñana J; Jordá-Marcos R; Maraví-Poma E; Torres-Martí A; Nava J; Martínez-Pellús A; Palomar M; Barcenilla F;
Intensive Care Med; 2001 Mar; 27(3):493-502. PubMed ID: 11355117
[TBL] [Abstract][Full Text] [Related]
14. Investigation of the clinical breakpoints of piperacillin-tazobactam against infections caused by Pseudomonas aeruginosa.
Yamagishi Y; Terada M; Ohki E; Miura Y; Umemura T; Mikamo H
J Infect Chemother; 2012 Feb; 18(1):127-9. PubMed ID: 21814800
[TBL] [Abstract][Full Text] [Related]
15. Meropenem versus piperacillin/tazobactam for febrile neutropenia in pediatric patients: efficacy of piperacillin/tazobactam as a 1-h drip infusion four times a day.
Kobayashi R; Sano H; Matsushima S; Hori D; Yanagi M; Kodama K; Suzuki D; Kobayashi K
Int J Hematol; 2021 Mar; 113(3):430-435. PubMed ID: 33170417
[TBL] [Abstract][Full Text] [Related]
16. Frequency of Acute Kidney Injury Caused by Tazobactam/Piperacillin in Patients with Pneumonia and Chronic Kidney Disease: A Retrospective Observational Study.
Morimoto T; Nagashima H; Morimoto Y; Tokuyama S
Yakugaku Zasshi; 2017; 137(9):1129-1136. PubMed ID: 28867699
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, safety, and tolerance of piperacillin/tazobactam compared to co-amoxiclav plus an aminoglycoside in the treatment of severe pneumonia.
Speich R; Imhof E; Vogt M; Grossenbacher M; Zimmerli W
Eur J Clin Microbiol Infect Dis; 1998 May; 17(5):313-7. PubMed ID: 9721959
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study.
Réa-Neto A; Niederman M; Lobo SM; Schroeder E; Lee M; Kaniga K; Ketter N; Prokocimer P; Friedland I
Curr Med Res Opin; 2008 Jul; 24(7):2113-26. PubMed ID: 18549664
[TBL] [Abstract][Full Text] [Related]
19. Clinical evaluation of the need for carbapenems to treat community-acquired and healthcare-associated pneumonia.
Kamata K; Suzuki H; Kanemoto K; Tokuda Y; Shiotani S; Hirose Y; Suzuki M; Ishikawa H
J Infect Chemother; 2015 Aug; 21(8):596-603. PubMed ID: 26070781
[TBL] [Abstract][Full Text] [Related]
20. [Laboratory and clinical studies on tazobactam/piperacillin in the field of pediatrics].
Kuno K; Ogawa A; Hayakawa F; Miyajima Y; Takahashi H; Okumura A; Kato T; Itomi K
Jpn J Antibiot; 1998 Jun; 51(6):395-406. PubMed ID: 9755829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
